This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street @themotleyfool #stocks $NTLA
Intellia Therapeutics innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.…
8,600$
-0,80%
Echtzeit-Aktienkurs Intellia Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Intellia Therapeutics Inc. Aktie
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
[Latest] Global Genetic Engineering Market Size/Share Worth USD 2,917.2 Million by 2033 at a 6.74% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
Intellia Therapeutics Announces CFO Transition
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
Intellia Therapeutics: "buy"
Charlotte, NC (www.aktiencheck.de) - Rating-Update:
Die Analysten von Truist stufen die Aktie von Intellia Therapeutics Inc. (ISIN: US45826J1051, WKN: A2AG6H, Ticker-Symbol:…
Global Genome Editing Market Size To Worth USD 34.75 Billion By 2033 | CAGR Of 16.19%
The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market…
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…
Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
…
Earnings call: Intellia Therapeutics reports robust Q1 progress By Investing.com
Earnings call: Intellia Therapeutics reports robust Q1 progress…
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
Is Intellia Therapeutics Stock a Buy Now?
The companys future will depend on its innovative qualities.…
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
2024 could see the start of its first late-stage clinical trials.…